Results 21 to 30 of about 2,611 (175)
Background Severe pruritus is a challenging condition, and it is more difficult to deal with in older patients due to their limitations in taking oral medication because of underlying diseases, possible interaction with concurrent medications, and poor ...
Jungsoo Lee +4 more
semanticscholar +1 more source
JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni +6 more
wiley +1 more source
Hell's Itch: A Self‐Case Report
ABSTRACT Hell's itch is a severely distressing dermatological condition characterized by the onset of incessant itching and intolerable pain 2–3 days post‐sunburn. It is underdiagnosed and underreported, and no definitive management framework has yet been developed.
Kai Peter Moors, Willem I. Visser
wiley +1 more source
The aim of this double-blinded, vehicle-controlled study was to test the antipruritic efficacy of topical strontium to relieve a nonhistaminergic form of itch that would be clinically relevant for chronic pruritic diseases.
Alexandru D. P. Papoiu +5 more
semanticscholar +1 more source
Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab
ABSTRACT Lichen amyloidosis (LA) is a chronic, pruritic dermatosis with papillary dermal amyloid deposition. Standard therapies often fail, and most reports of dupilumab in LA involve patients with concomitant atopic dermatitis. We report a 32‐year‐old man with refractory, non‐atopic LA who had failed topical corticosteroids, tacrolimus, phototherapy ...
Sohrab Elahwiesy +5 more
wiley +1 more source
Emerging Paediatric Uses of Dupilumab Beyond Approvals
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese +11 more
wiley +1 more source
To explore the mechanism of Qiwei antipruritic by using network pharmacology and molecular docking technology.The components and related targets of Qiwei antipruritic were screened by using the traditional Chinese medicine system pharmacology database (TCMSP and symmap databases).
Wang,Luoxi +3 more
openaire +4 more sources
ABSTRACT Background Uremic pruritus (UP) remains a common and distressing complication in patients with end‐stage renal disease (ESRD) receiving maintenance hemodialysis. The burden is particularly pronounced in low‐ and middle‐income countries where twice‐weekly hemodialysis is frequently practiced because of resource limitations. Gabapentin is widely
Bilal Mohsin +9 more
wiley +1 more source
Impairment of health‐related quality of life in patients with PBC, in particular observed in younger female, represents distinct dimensions of disease impact, independently of long‐term outcomes. Overall and interindividual changes in PBC‐40 scores greatly varied over 10 years, suggesting that symptom burdens are driven by heterogeneous underlying ...
Akihito Takeuchi +22 more
wiley +1 more source
Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis
Chronic prurigo, including prurigo nodularis, is a chronic, often treatment‐refractory condition characterized by persistent pruritus and chronic scratch lesions. Advances in the understanding of its underlying pathophysiology have enabled the development of novel targeted therapies; however, management remains challenging due to the expanding range of
Simon M. Mueller +11 more
wiley +1 more source

